Prospective Randomized Controlled trial of low dose long term Peg-Interferon alpha-2a treatment after curative ablation for Hepatocellular Carcinoma.

Trial Profile

Prospective Randomized Controlled trial of low dose long term Peg-Interferon alpha-2a treatment after curative ablation for Hepatocellular Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ursodeoxycholic acid
  • Indications Hepatitis C; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top